Can a smart drug missile tame Hard-to-Treat leukemia?
NCT ID NCT01134575
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial is investigating whether a targeted drug called CMC-544 (inotuzumab ozogamicin), given alone or later combined with rituximab, can control acute lymphoblastic leukemia (ALL) that has returned or not responded to standard treatment. The study enrolls adults and older children with relapsed or refractory ALL. Researchers are measuring how many patients achieve complete or partial remission to see if this approach offers a meaningful benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a targeted antibody-drug conjugate called inotuzumab ozogamicin (CMC-544), given alone or later combined with rituximab
- What this could lead to
- If effective, this approach could offer a new treatment option for patients with hard-to-treat ALL that has returned or not responded to prior therapy.
- What could go wrong
- This is a mid-stage trial with a modest number of participants, so results may not confirm benefit. The drug can cause serious side effects, including liver toxicity and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- Can a targeted drug combo beat the toughest childhood leukemia?